SLC5A2 and chronic kidney disease: Recently, emerging evidence showed that antidiabetic agents, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors like empagliflozin and dapagliflozin, have demonstrated the ability to reduce the amount of albuminuria and inhibited CKD progression in patients with DKD and non-diabetic CKD [21,22].